Bacterial virulence factors and uses thereof
AssigneesUniversidad Nacional Autonoma De Mexico, The University of British Columbia
InventorsBrett Finlay, Samantha Gruenheid, Wanyin Deng, Bruce A. Vallance, Jose L. Puente
Life of this patent
Estimating the term…
Abstract
The invention relates to, in part, secreted proteins of bacterial pathogens and methods for their use. More specifically, the invention provides in part several new common secreted proteins for A/E pathogens. In some embodiments of the invention, these polypeptides and nucleic acid molecules encoding these polypeptides, or portions thereof, are useful as vaccines, diagnostics, or drug screening tools for A/E pathogenic infections, or as reagents.
Claims17
A method for increasing the production of a polypeptide secreted by a Type III secretion system (TTSS), the method comprising:
- a) providing an A/E pathogenic cell comprising a recombinant Orf11/Global Regulator of LEE Activator (GrlA) nucleic acid molecule derived from an A/E pathogen;
- b) expressing an Orf11/GrlA polypeptide encoded by the recombinant Orf11/GrlA nucleic acid molecule, and
- c) growing the A/E pathogenic cell under conditions that favour secretion of Type III antigens, whereby the production of the polypeptide secreted by a Type III secretion system (TTSS), is increased when compared to an A/E pathogenic cell that does not comprise the recombinant Orf11/GrlA nucleic acid molecule.
A method for increasing the production of a polypeptide secreted by a Type III secretion system (TTSS), the method comprising:
- a) introducing a recombinant Orf11/GrlA nucleic acid molecule derived from an A/E pathogen into an A/E pathogenic cell;
- b) expressing an Orf11/GrIA polypeptide encoded by the recombinant Orf11/GrlA nucleic acid molecule, and
- c) growing the A/E pathogenic cell under conditions that favor secretion of Type III antigens, whereby the production of the polypeptide secreted by a Type III secretion system (TTSS), is increased when compared to an A/E pathogenic cell that does not comprise the recombinant Orf11/GrlA nucleic acid molecule.
Dependencies are inferred from the claim text.